Can topical mitomycin prevent laryngotracheal stenosis?

Area of Science:

• Otolaryngology
• Regenerative Medicine
• Pharmacology

Background:

• Laryngotracheal stenosis (LTS) is a serious condition that can lead to airway obstruction.
• Current treatments for LTS are often invasive and may have limited efficacy.
• Early intervention with topical agents is being explored to prevent or mitigate LTS.

Purpose of the Study:

• To evaluate the efficacy of early topical mitomycin application in preventing or reducing laryngotracheal stenosis (LTS) in a canine model.
• To compare the effects of a single mitomycin application versus repeat application.

Main Methods:

• A prospective, controlled animal study involving 60 dogs with induced LTS.
• Dogs were randomized into four groups: control (saline), suction-control (saline with suction), mitomycin (single application), and repeat-mitomycin (two applications).
• Laryngeal lumen measurements were taken endoscopically at baseline, day 12, and day 21.

Main Results:

• All dogs in the mitomycin groups survived to day 21, significantly higher than control and suction groups.
• Single topical mitomycin application resulted in significantly reduced stenosis (median 27%) compared to controls (85-95%) at day 21.
• Repeat mitomycin application did not offer additional benefit over a single application.

Conclusions:

• A single topical application of mitomycin effectively reduces the severity of laryngotracheal stenosis in dogs.
• Repeat application of mitomycin did not improve outcomes.
• These findings support the need for prospective clinical studies to investigate mitomycin's efficacy in human LTS treatment.